The Yin-Yang balance of SIRT1 and SIRT2 in cancer metabolic remodeling

TL;DR

SIRT1 and SIRT2 regulate cancer metabolism in opposing ways, influencing tumor growth and immune responses, and targeting their balance could lead to new cancer therapies.

Contribution

The paper introduces the Yin-Yang regulatory balance of SIRT1 and SIRT2 in cancer metabolism and their therapeutic targeting potential.

Findings

SIRT1 and SIRT2 modulate glucose, lipid, and mitochondrial metabolism in cancer cells.

SIRT2 acts as a metabolic checkpoint for CD8⁺ T cells, suggesting a role in immune checkpoint therapy.

Autophagy is a key node regulated by both SIRT1 and SIRT2 in tumor metabolic adaptation.

Abstract

Sirtuin 1 (SIRT1) and Sirtuin 2 (SIRT2) are NAD⁺-dependent deacetylases that regulate cancer metabolic stress, exerting their effects primarily through post-translational modification of metabolic enzymes and transcription factors. They modulate glucose, lipid, and mitochondrial metabolism, as well as immune metabolism responses within the tumor microenvironment. Depending on cellular context, they can promote or suppress tumor growth by directing energy production, redox balance, and metabolic adaptation. These context-dependent and often opposing activities constitute a Yin-Yang mode of regulation in cancer metabolism, reflecting a dynamic balance between metabolic activation and constraint. Autophagy has emerged as a critical metabolic integration node regulated by both SIRT1 and SIRT2, linking nutrient sensing, mitochondrial quality control, and stress adaptation. This review summarizes recent advances in understanding how SIRT1 and SIRT2 coordinate tumor metabolism and discusses therapeutic strategies that target their regulatory balance to reprogram cancer metabolism. SIRT2 also functions as a metabolic checkpoint that restrains CD8⁺ T cell effector metabolism, providing a rationale for combining SIRT2 inhibition with immune checkpoint blockade in metabolically stressed tumor microenvironments.

Figures